Relay Therapeutics Inc

RLAY

Healthcare|Biotechnology|USA

$20.00

-0.74 (-3.59%)

Tangible Book

$3.39

Earnings Power

$3247.43

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	PIK3CA Mutation, HER2- Negative Breast Cancer	P3	Recruiting	540	RCT, Open-label	RLY-2608, Capivasertib, Fulvestrant
NCT06789913 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)	PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations	P2	Recruiting	277	RCT, Open-label	RLY-2608, Placebo
NCT07584226 A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors	Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors	P1	Recruiting	35	Open-label	RLY-8161
NCT05216432 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	PIK3CA Mutation, Solid Tumor, Adult	P1	Recruiting	930	Open-label	RLY-2608, Fulvestrant, Palbociclib 125mg, Ribociclib 400mg, Ribociclib 600mg, PF-07220060 100mg, PF-07220060 300 mg
NCT05759949 First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors	PIK3CA Mutation, Solid Tumor, Adult	P1	Completed	41	Open-label	RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
NCT04622527 A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study	Anxiety, Burn Out	N/A	Completed	24	RCT, Single-blind	—
NCT04241055 Values Affirmation to Improve Teachers' Outcomes	Psychological	N/A	Terminated	500	RCT, Double-blind	—